(SWOG S1117) A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndro...

PrintE-mail
Title (SWOG S1117) A Randomized Phase II Study of Azacitidine in Combination with Lenalidomide (NSC-703813) vs. Azacitidine Alone vs. Azacitidine in Combination with Vorinostat (NSC-701852) for Higher-Risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
Contact JK
Principal Investigator Eunice Wang, MD
Study Number 220012
Phase2
Summary To test whether the response rate (complete remission, partial remission, or hematologic improvement) of patients with higher-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who receive either the combination of lenalidomide and azacitidibe or the combination of vorinostat and azacitidine is improved compared to patients who receive single-agent azacitidine.
Eligibility See ClinicalTrials.Gov link for eligibility criteria.
For more information about the clinical study go to Clinicaltrial.Gov